Breo Ellipta (fluticasone furoate/vilanterol) Inhalation Powder
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
February 2016
ADVERSE REACTIONS
Post-Marketing Experience
Musculoskeletal and Connective Tissue Disorders
Muscle Spasms
...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts